Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease
Science Translational Medicine · 14.06.2023 · 15 (700)
DOI: 10.1126/scitranslmed.abo2984 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 14.06.2023. Verfasst von Aura L Ferreiro und 19 weiteren Autor:innen. Beteiligte Einrichtung: Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Alzheimer Disease, Microbiota. Die Arbeit wurde bisher 380-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIH HHS, NIDDK NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) pathology is thought to progress from normal cognition through preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work suggests that the gut microbiome of symptomatic patients with AD has an altered taxonomic composition compared with that of healthy, cognitively normal control individuals. However, knowledge about changes in the gut microbiome before the onset of symptomatic AD is limited. In this cross-sectional study that accounted for clinical covariates and dietary intake, we compared the taxonomic composition and gut microbial function in a cohort of 164 cognitively normal individuals, 49 of whom showed biomarker evidence of early preclinical AD. Gut microbial taxonomic profiles of individuals with preclinical AD were distinct from those of individuals without evidence of preclinical AD. The change in gut microbiome composition correlated with β-amyloid (Aβ) and tau pathological biomarkers but not with biomarkers of neurodegeneration, suggesting that the gut microbiome may change early in the disease process. We identified specific gut bacterial taxa associated with preclinical AD. Inclusion of these microbiome features improved the accuracy, sensitivity, and specificity of machine learning classifiers for predicting preclinical AD status when tested on a subset of the cohort (65 of the 164 participants). Gut microbiome correlates of preclinical AD neuropathology may improve our understanding of AD etiology and may help to identify gut-derived markers of AD risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA.
- Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Program in Occupational Therapy, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110, USA.
ORCID-Profile: Aura L Ferreiro, JooHee Choi, Jian Ryou, Erin P Newcomer, Regina Thompson, Rebecca M Bollinger, Laurie Sax, Tammie L S Benzinger, David M Holtzman, Suzanne E Schindler, Carlos Cruchaga, Omar H Butt, John C Morris, Phillip I Tarr, Beau M Ances, Gautam Dantas
Förderung
- NIA NIH HHS
- NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Ferreiro, A. L., Choi, J., Ryou, J., Newcomer, E. P., Thompson, R., Bollinger, R. M., Hall-Moore, C., Ndao, I. M., Sax, L., Benzinger, T. L. S., Stark, S. L., Holtzman, D. M., Fagan, A. M., Schindler, S. E., Cruchaga, C., Butt, O. H., Morris, J. C., Tarr, P. I., Ances, B. M., & Dantas, G. (2023). Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease. Science Translational Medicine, 15(700). https://doi.org/10.1126/scitranslmed.abo2984
Vancouver
Ferreiro AL, Choi J, Ryou J, Newcomer EP, Thompson R, Bollinger RM, et al. Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease. Science Translational Medicine. 2023;15(700). doi:10.1126/scitranslmed.abo2984
BibTeX
@article{Ferreiro2023,
author = {Ferreiro, Aura L and Choi, JooHee and Ryou, Jian and Newcomer, Erin P and Thompson, Regina and Bollinger, Rebecca M and Hall-Moore, Carla and Ndao, I Malick and Sax, Laurie and Benzinger, Tammie L S and Stark, Susan L and Holtzman, David M and Fagan, Anne M and Schindler, Suzanne E and Cruchaga, Carlos and Butt, Omar H and Morris, John C and Tarr, Phillip I and Ances, Beau M and Dantas, Gautam},
title = {Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {700},
doi = {10.1126/scitranslmed.abo2984}
}
EUVIMED